Skip to main content

Market Overview

Ascendis Pharma's TransCon PTH Provides Durable Benefit, Is Well Tolerated Even After One Year Treatment In Hypoparathyroidism

Share:
Ascendis Pharma's TransCon PTH Provides Durable Benefit, Is Well Tolerated Even After One Year Treatment In Hypoparathyroidism
  • Ascendis Pharma A/S (NASDAQ: ASND) has announced preliminary 58-week results from the continuing open-label extension (OLE) portion of the Phase 2 PaTH Forward Trial evaluating TransCon PTH in adult subjects with hypoparathyroidism (HP).
  • Key Findings of the Preliminary OLE Results:
    • Fifty-eight subjects continue in the open-label extension beyond 58 weeks as of May 7.
    • Data showed established physiologic calcium metabolism based upon normalization of 24-hour urine calcium excretion and a downward trend toward mid-normal levels in bone markers without using therapeutic calcium and vitamin D supplementation.
    • No treatment-related serious or severe adverse events occurred, and no treatment-emergent adverse events led to discontinuation of the study drug.
  • In addition to PaTH Forward, Ascendis Pharma is conducting the PaTHway Phase 3 trial in North America and Europe, evaluating the safety, tolerability, and efficacy of TransCon PTH.
  • Topline results are expected by the end of this year.
  • TransCon PTH is an investigational once-daily long-acting prodrug of parathyroid hormone (PTH[1-34]) designed to restore PTH at physiologic levels 24 hours each day.
  • Price Action: ASND shares closed 2% lower at $130.07 on Monday.
 

Related Articles (ASND)

View Comments and Join the Discussion!

Posted-In: Briefs HypoparathyroidismBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com